ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brexpiprazole

Also written as “Brexpiprazole”, “OPC-34712” and “Brexpiprazole (OPC-34712)”.

Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Stress Disorders, Post-Traumatic · Alzheimer Disease · Mania, led by 3 companies.

Drug pageBrexpiprazole: every studyAll 79 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 29, 202170 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka600 open or runningphase 4since Mar 29, 2021Nov 24, 2008none ahead
H. Lundbeckits history only90 open or runningphase 3since Mar 11, 2013Mar 11, 2013none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Dec 4, 2025Dec 4, 2025none ahead

Also a collaborator on its studies: Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 42 studies since Nov 24, 2008.

  1. Apr 13, 2018Phase 3 study in Depressive Disorder, MajorNCT03538691 · 1,149 enrolled · United States
  2. May 7, 2018Phase 3 study in Alzheimer DiseaseNCT03548584 · 345 enrolled · United States
  3. Jul 11, 20183 phase 3 studiesNCT03594123, NCT03697603, NCT03737474
  4. Aug 5, 2018Phase 3 study in Agitation Associated With Dementia of the Alzheimer's TypeNCT03620981 · 410 enrolled · Japan
  5. Oct 28, 2018Phase 3 study in Agitation Associated With Dementia of the Alzheimer's TypeNCT03724942 · 164 enrolled · Japan
  6. Nov 2, 20182 phase 1 studiesNCT03734354, NCT03734302
  7. Mar 12, 2019Phase 3 study in SchizophreniaNCT03874494 · 371 enrolled · China
  8. Sep 20, 2019Phase 2 study in Borderline Personality DisorderNCT04100096 · 332 enrolled · United States, Spain, Ukraine
  9. Oct 10, 2019Phase 3 study in Stress Disorders, Post-TraumaticNCT04124614 · 450 enrolled · United States
  10. Nov 20, 20192 phase 3 studiesNCT04174365, NCT04174170
  11. Dec 2, 2019Phase 3 study in Borderline Personality DisorderNCT04186403 · 201 enrolled · United States
  12. Feb 4, 2020Phase 3 study in Autistic DisorderNCT04258839 · 95 enrolled · United States
  13. Mar 29, 2021Phase 4 study in Depressive Disorder, MajorNCT04830215 · 122 enrolled · Canada
  14. May 31, 2022Phase 4 study in Depressive Disorder, MajorNCT05504486

TargetBeta

“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131

Studies

All 60 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05504486Depressive Disorder, Major4WithdrawnMar 22, 20230
NCT04830215Depressive Disorder, Major · Canada4CompletedMay 27, 2022122
NCT04258839Autistic Disorder · United States3CompletedMar 16, 202395
NCT04186403Borderline Personality Disorder · United States3CompletedSep 22, 2021201
NCT04174170Stress Disorders, Post-Traumatic · United States3CompletedJul 25, 2023591
NCT04174365Autistic Disorder · United States3CompletedAug 8, 2022119
NCT04124614Stress Disorders, Post-Traumatic · United States3CompletedJul 19, 2023450
NCT04100096Borderline Personality Disorder · United States, Spain, Ukraine2CompletedJun 27, 2021332
NCT03874494Schizophrenia · China3CompletedAug 6, 2021371
NCT03734354Health · China1CompletedMay 18, 202030
NCT03734302Healthy · China1CompletedJun 10, 202010
NCT03724942Agitation Associated With Dementia of the Alzheimer's Type · Japan3CompletedDec 2, 2021164
NCT03620981Agitation Associated With Dementia of the Alzheimer's Type · Japan3CompletedApr 21, 2023410
NCT03737474Depressive Disorder, Major · Japan3CompletedMar 17, 2021248
NCT03697603Depressive Disorder, Major · Japan3CompletedJun 6, 2022740
NCT03594123Alzheimer Disease · United States3CompletedSep 19, 2022259
NCT03548584Alzheimer Disease · United States3CompletedMay 23, 2022345
NCT03538691Depressive Disorder, Major · United States3CompletedJul 8, 20221,149
NCT03487198Depressive Disorder, Major · China3TerminatedMay 30, 201965
NCT03292848Attention Deficit Disorder with Hyperactivity · United States1CompletedMay 21, 201824
NCT03287869Mania · United States, Bulgaria, Croatia and more3CompletedJul 31, 2019381
NCT03259555Mania · United States, Bulgaria, Poland and more3CompletedJan 2, 2019322
NCT03257865Mania · United States, Croatia, Ukraine3CompletedJan 22, 2019333
NCT03238326Schizophrenia · United States, France, Italy and more3CompletedApr 22, 2025295
NCT03198078Schizophrenia · United States3CompletedApr 3, 2023316
NCT03033069Stress Disorders, Post-Traumatic · United States2CompletedNov 12, 2018336
NCT02968121Schizophrenia · United States1TerminatedDec 14, 201722
NCT02875080Healthy Adult Male · Japan1CompletedNov 27, 201618
NCT02212613Depressive Disorder, Major · United States3WithdrawnNov 20150
NCT02196506Depressive Disorder · United States, Germany, Hungary and more3CompletedApr 2016837
NCT02194933Schizophrenia · United States3CompletedApr 201638
NCT02411695Schizophrenia · United States1CompletedJan 1, 201743
NCT02054702Schizophrenia3CompletedJun 201497
NCT02013622Schizophrenia · United States3CompletedSep 201449
NCT02013609Schizophrenia · United States3CompletedSep 201448
NCT02013531Depressive Disorder, Major · United States3CompletedMay 201437
NCT02012218Depressive Disorder, Major · United States3CompletedOct 201461
NCT01922258Alzheimer Disease · United States, Bulgaria, Canada and more3CompletedMar 2017270
NCT01862640Alzheimer Disease · United States, Croatia, Germany and more3CompletedMar 15, 2017433
NCT01854944Schizophrenia · United States1CompletedJul 201412
NCT01727726Depressive Disorder · United States, Canada, France and more3CompletedOct 17, 20162,182
NCT01668797Acute Schizophrenia · United States, Colombia, Malaysia and more3CompletedJan 2015524
NCT01670279Depressive Disorder, Major · United States1CompletedMay 201318
NCT01649557Schizophrenia · United States, Bulgaria, Croatia and more2CompletedAug 2011244
NCT01456897Schizophrenia · Japan3CompletedMay 2015282
NCT01451164Schizophrenia · Japan3CompletedJun 2015459
NCT01447576Depressive Disorder, Major · United States2CompletedDec 20121,036
NCT01423916Schizophrenia · United States1CompletedFeb 2012218
NCT01397786Schizophrenia · United States, Canada, Colombia and more3CompletedJan 20161,044
NCT01396421Acute Schizophrenia · United States, Canada, Japan and more3CompletedJan 2014636
NCT01393613Acute Schizophrenia · United States, Colombia, Croatia and more3CompletedFeb 2014674
NCT01360645Depressive Disorder · United States, Canada, France and more3CompletedMay 2013826
NCT01360632Depressive Disorder · United States, Canada, Germany and more3CompletedAug 20131,539
NCT01299454Schizophrenia · United States1CompletedJun 201145
NCT01289080Schizophrenia · United States1CompletedDec 201119
NCT01074294Attention Deficit Disorder with Hyperactivity · United States2CompletedJun 20, 2011740
NCT01052077Depressive Disorder, Major · United States2CompletedOct 2011773
NCT00905307Schizophrenia · United States, Bulgaria, Croatia and more2CompletedSep 2010459
NCT00805454Schizophrenia1CompletedJul 200915
NCT00797966Depressive Disorder, Major · United States2CompletedJun 2010850

How it is read

Names in the registry

  • “Brexpiprazole”, 44 entries
  • “OPC-34712”, 17 entries
  • “Brexpiprazole (OPC-34712)”, 2 entries
  • “Brexpiprazole, OPC-34712”, 2 entries
  • “OPC-34712 + ADT”, 2 entries

Codes read as this program: OPDC34712.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.